Development of erythroleukaemia after myelodysplastic syndrome in a patient with Wegener's granulomatosis.
Takaoka
T
T
Matsukawa
Y
Y
Tomita
Y
Y
Kitamura
N
N
Yamazaki
T
T
Takeuchi
J
J
Nishinarita
S
S
Sawada
U
U
Horie
T
T
D003520:Cyclophosphamide / Q000009:adverse effects; D017809:Fatal Outcome; D005260:Female; D014890:Granulomatosis with Polyangiitis / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D004915:Leukemia, Erythroblastic, Acute / Q000139:chemically induced*; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000209:etiology*
D007166:Immunosuppressive Agents; D003520:Cyclophosphamide